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The plasminogen activation system represents a complex enzy-
matic cascade which plays a key role in fibrinolysis, tissue remod-
elling and invasive processes, including cancer (Danø et al, 1985;
Rijken, 1995). Central to this system is the conversion of the inac-
tive pro-enzyme plasminogen to plasmin, which is able to dissolve
fibrin clots, degrade extracellular matrix proteins and activate
latent pro-metalloproteases (Danø et al, 1985; Conese and Blasi,
1995; Rijken, 1995). Two enzymes, i.e. urokinase-type plas-
minogen activator (uPA) and tissue-type plasminogen activator
(tPA), are both efficient activators of plasminogen. Unlike uPA,
tPA has a strong affinity for fibrin, the presence of which strongly
enhances tPA activity (Mignatti and Rifkin, 1993). Thus, both
plasminogen activators have different physiological roles, uPA
mediating tissue remodelling processes in a variety of normal and
pathological conditions, whereas tPA is primarily involved in
thrombolysis (Danø et al, 1985; Mignatti and Rifkin, 1993; Rijken,
1995). The activity of uPA and tPA is controlled in part by two
main specific inhibitors, plasminogen activator inhibitor type-1
(PAI-1) and type-2 (PAI-2), which form inactive complexes of 1:1
stoichiometry with the plasminogen activators (Conese and Blasi,
1995; Rijken, 1995). Both uPA and PAI-1 are established prog-
nostic factors in several types of cancer, a high tissue level of both
components generally being associated with tumour progression
and with poor disease-free and/or overall survival (reviewed by
Duffy, 1996; Schmitt et al, 1997). Furthermore, several investiga-
tors have reported on the potential diagnostic and prognostic rele-
vance of tPA analysed either in plasma or in tumour tissues from
patients, including those afflicted with breast or colon cancer
(Layer et al, 1987; De Bruin et al, 1988; Duffy et al, 1988;
Needham et al, 1988; Grøndahl-Hansen et al, 1990; Jänicke et al,
1990, 1991; Rella, et al, 1993; Yamashita et al, 1993, 1995;
Duggan et al, 1997). In addition, some studies even have examined
the presence of complexes between tPA and PAI-1 in plasma from
healthy individuals and patients with various diseases (Niwano et
al, 1992; Hansson et al, 1994; Maser et al, 1997). In these different
studies referred to above, ELISA methods have mostly been
employed. Recently, a new ELISA suitable for the assessment of
tPA in breast tumour tissue was developed (Grebenschikov et al,
1997). This ELISA, based on a combination of polyclonal anti-
bodies, is easily adaptable to the assessment of its complex with
PAI-1. In the present study, we applied the ELISA to the determi-
nation of tPA and tPA:PAI-1 complex in breast tumour cytosols
and detergent extracts of the corresponding high-speed pellets.
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Summary The prognostic value of tissue-type plasminogen activator (tPA) measured in samples derived from 865 patients with primary
breast cancer using a recently developed enzyme-linked immunosorbent assay (ELISA) was evaluated. Since the assay could easily be
adapted to the assessment of the complex of tPA with its type-1 inhibitor (PAI-1), it was investigated whether the tPA:PAI-1 complex also
provides prognostic information. To this end, cytosolic extracts and corresponding detergent extracts of 100 000 g pellets obtained after
ultracentrifugation when preparing the cytosolic fractions for routine steroid hormone receptor determination were assayed. Statistically
significant correlations were found between the cytosolic levels and those determined in the pellet extracts (Spearman correlation coefficient
rs = 0.75, P < 0.001 for tPA and r = 0.50, P < 0.001 for tPA:PAI-1 complex). In both Cox univariate and multivariate analysis elevated levels of
(total) tPA determined in the pellet extracts, but not in cytosols, were associated with prolonged relapse-free (RFS) and overall survival (OS).
In contrast, high levels of the tPA:PAI-1 complex measured in cytosols, but not in the pellet extracts, were associated with a poor RFS and OS.
The prognostic information provided by the cytosolic tPA:PAI-1 complex was comparable to that provided by cytosolic (total) PAI-1.
Furthermore, the estimated levels of free, uncomplexed tPA and PAI-1, in cytosols and in pellet extracts, were related to patient prognosis in
a similar way as the (total) levels of tPA and PAI-1 respectively. Determination of specific forms of components of the plasminogen activation
system, i.e. tPA:PAI-1 complex and free, uncomplexed tPA and/or PAI-1, may be considered a useful adjunct to the analyses of the separate
components (tPA and/or PAI-1) and provide valuable additional prognostic information with respect to survival of breast cancer patients.
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complex in both types of samples was subsequently evaluated.
Furthermore, we analysed the prognostic value of the calculated
PAI-1 to tPA ratio and of the free, uncomplexed forms of both PAI-1
and tPA.
MATERIALS AND METHODS
Patients and tumour characteristics
This study was performed on a group of 865 patients with operable
primary breast cancer in whom tPA antigen levels were measured
in both cytosols and pellet extracts. The patients, whose samples
were stored in the tumour bank of the Rotterdam Cancer Institute
(Dr Daniel den Hoed Kliniek), included those for which tumour
levels of uPA and PAI-1 were determined previously (De Witte
et al, 1998). Patients with primary diagnosis of breast cancer
between 1979 and 1989, without evidence of distant metastasis at
the time of diagnosis, were included in the study. Patients with
previous diagnosis of carcinoma, except for basal cell skin cancer
or cervical cancer stage Ia, or with evidence of disease within
1 month after primary surgery were excluded. None of the patients
received neo-adjuvant treatment before primary surgery. In case of
mastectomy for residual disease after an initial lumpectomy, the
mastectomy is considered (as part of) primary treatment. The
median number of lymph nodes removed surgically was 11.
Median age of the patients at the time of surgery was 56 years
(range 25–89 years). Radiotherapy was given to 82% of the
patients: on the breast/thoracic wall to 596 patients and/or on the
axilla to 250 patients, and/or on one or more lymph node areas
other than the axilla to 283 patients. Two of the 434 node-
negative patients received adjuvant chemotherapy (CMF-cyclo-
phosphamide, methotrexate, 5-fluorouracil), while none of these
patients received adjuvant endocrine therapy. Of the 422 node-
positive patients (for nine patients, nodal status missing),
adjuvant chemotherapy was given to 138 patients, while 59
patients received hormonal therapy, either alone (45 patients) or in
Table 1 Relationships of tPA and tPA:PAI-1 complex levels in 865 cytosols and pellet extracts with patient and tumour characteristics
Percentage of tumours above the median valueb
Characteristics Number of tPAc
c tPAp
c tPA:PAI-1c
c tPA:PAI-1p
c
patientsa complex complex
All patients 865 50 50 50 50
Age at surgery (years)
≤ 4 0 1 1 73 33 14 84 1
41–55 297 54 56 46 46
56–70 291 48 48 53 55
> 70 160 57 56 53 54
P-valued 0.004 0.005 0.008 0.009
Menopausal status
Pre-menopausal 353 51 49 47 44
Post-menopausal 512 49 51 52 54
P-valuee 0.80 0.50 0.02 0.004
Tumour size
T1 (≤ 2 cm) 395 53 58 51 53
T2 (> 2–5 cm) 389 48 44 50 48
T3/4 (> 5 cm) 81 42 38 47 45
P-valuef < 0.001 < 0.001 0.79 0.01
Nodal status
N0 434 50 55 48 50
N1–3 209 50 48 55 54
N>3 213 48 43 49 45
P-valuef 0.23 < 0.001 0.45 0.07
Grade
Well/moderate 151 56 62 49 51
Poor 496 44 45 51 52
P-valuee < 0.001 < 0.001 0.81 0.67
ER-positiveg
No 201 18 18 38 35
Yes 663 59 60 53 54
P-valued < 0.001 < 0.001 < 0.001 < 0.001
PgR-positiveg
No 240 24 25 42 44
Yes 611 60 60 53 52
P-valued < 0.001 < 0.001 < 0.001 0.002
aDue to missing values the numbers do not always add up to 865; values for tPA:PAI-1c and tPA:PAI-1p correspond to 782 and 822 patients, respectively.
bMedian antigen levels for tPAc, tPAp, tPA:PAI-1c and tPA:PAI-1p as indicated in the legend to Table II. ctPAc, tPAp, tPA:PAI-1c and tPA:PAI-1p denotes tPA and
tPA:PAI-1 complex levels determined with the different ELISAs in cytosols (c) and pellet extracts (p), respectively. dP-value for Spearman rank correlation.
eP-value for Wilcoxon rank-sum test (for grade: well and moderate combined). fP-value for Kruskal–Wallis test, including a Wilcoxon-type test for trend. gCut-off
point used for ER and PgR: 10 fmol mg–1 protein.288 JH de Witte et al
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combination with chemotherapy (14 patients). All patients were
routinely examined every 3–6 months during the first 5 years of
follow-up and once a year thereafter (median follow-up period
of patients alive, 100 months; range, 12–167 months). During
follow-up, 354 patients (41%) showed relapse and counted as
failures in the analysis for relapse-free survival (RFS). Sixty-two
patients (7%) died without evidence of disease and were censored
at last follow-up in the analysis for RFS. Two-hundred and four-
teen patients (25%) died after a previous relapse. A total of 276
(62+214) patients (32%) were counted as failures in the analysis
for overall survival (OS). Further characteristics of patients and
tumours are listed in Table 1.
Tumour tissue extraction
Tumour tissues (stored in liquid nitrogen) were processed in the
frozen state by pulverization with a microdismembrator and the
resulting tissue powders homogenized in buffer (10 mM K2HPO4,
containing 1.5 mM di-potassium chloride EDTA, 3 mM sodium
azide, 10 mM monothioglycerol and 10% (v/v) glycerol, pH = 7.4),
as recommended by the European Organization for Research and
Treatment of Cancer for analysis of steroid hormone receptors
(oestrogen (ER and PgR) (EORTC Breast Cancer Cooperative
Group, 1980). The homogenates were centrifuged for 30 min at
100 000 g and 4°C to obtain the supernatant fractions (cytosols).
The 100 000 g pellets were re-homogenized with an Ultraturrax
tissue homogenizer in 20 mM Tris-HCl (pH = 8.5) containing 125
mM sodium chloride, after complete removal of the 50% (v/v)
glycerol under which the pellets were interimly stored at –80°C.
After adding Triton X-100 to a final concentration of 1%, the
homogenates (total volume 1500 ml) were subsequently incubated
for 16–20 h at 4°C under gentle shaking. The supernatant fractions
obtained by centrifugation at 30 000 g at 4°C were designated as
pellet extracts.
Steroid hormone receptor assays
ER and PgR levels were determined by ligand binding assay or
enzyme immunoassay in cytosols as described earlier (Foekens
et al, 1989). The cut-off level used as to classify tumours as ER or
PgR positive or negative was 10 fmol mg–1 cytosolic protein.
ELISAs
ELISA for tPA
The antigen levels of tPA in cytosols and pellet extracts were
assessed with a newly established ELISA (Grebenschikov et al,
1997). Briefly, microtitreplates were first coated overnight at 4°C
with sheep anti-chicken IgY antibodies and then incubated with
the specific chicken antibodies directed against tPA. Bound ligand
was detected by incubation with rabbit anti-tPA antibodies and
subsequent incubation with horseradish peroxidase (HRP)-
labelled goat anti-rabbit antibodies (Sigma Chemical Co, St Louis,
MO, USA) diluted 1:23 000. Recombinant single-chain tPA
(Boehringer Ingelheim, Alkmaar, The Netherlands) was used as a
standard in the ELISA. The tPA ELISA detects both the free form
of tPA, as well as its complex with PAI-1 and PAI-2.
ELISA for tPA:PAI-1 complex
The tPA:PAI-1 complex in cytosols and pellet extracts was
determined in assay formats based on a combination of polyclonal
antibodies employed in the ELISAs for the separate components,
i.e. tPA and PAI-1 (Grebenschikov et al, 1997). Briefly, the
chicken anti-tPA and rabbit anti-PAI-1 antibody (ELISA format
A), and/or the chicken anti-PAI-1 and rabbit anti-tPA antibody
(ELISA format B) were combined as catching and tagging anti-
body in one and the same ELISA frame for assessment of tPA:
PAI-1 complex. Detection of complexes was performed with HRP-
labelled goat anti-rabbit antibodies as described above. The
tPA:PAI-1 complex standard was a gift from Prof. Andreasen
(University of Århus, Århus, Denmark), prepared from the sepa-
rate components as described previously (Egelund et al, 1997).
The tPA:PAI-1 complex in cytosols and pellet extracts was deter-
mined essentially in both ELISA formats, except for those cases in
which high levels of PAI-1 or tPA were to be expected; in these
cases only format A ([PAI-1]³10*[tPA]) or format B
([tPA]³10*[PAI-1]) was chosen, thereby anticipating an underesti-
mation of complex assessment because of possible competition of
(excess) uncomplexed PAI-1 or tPA with tPA:PAI-1 complex for
binding to the catching antibodies. At least two different dilutions
of each patient sample were analysed in ELISA format A and/or
format B, and the final concentration was calculated by extrapola-
tion to infinite dilution using linear regression. When applying
both ELISA formats, the highest antigen value obtained was
considered as representing the actual tPA:PAI-1 complex concen-
tration in the patient’s sample. Strong statistically significant
correlations were found between the antigen values obtained in
ELISA format A and format B (rs = 0.97, P < 0.001, for both the
cytosols and the pellet extracts). The calculated percentage of tPA
being in complex with PAI-1, the antigen levels expressed in
molars, varied to a large extent, both in cytosols (median: 44%;
inter-quartile range: 18–90%) and in pellet extracts (34%;
12–83%).
ELISA reagents were all diluted in phosphate-buffered saline
(PBS) with 1% bovine serum albumin (BSA) and 0.1% (v/v)
Tween-20. Incubations with standards, samples and controls,
diluted in PBS-BSA-Tween, were performed overnight at 4°C. All
determinations were performed in duplicate. Triton X-100 did not
influence the ELISA results up to a concentration of 1%. The
reproducibility of assay performance was controlled by analysis of
an aliquot of a pooled breast tumour cytosol sample (tPA ELISA)
or a pooled plasma sample (tPA:PAI-1 ELISA) in each assay-run
and the between-assay variation was found to be below 10% for
both ELISAs. The within-assay variation of samples measured in
duplicate was always below 5%.
Protein determinations
The Bradford method for protein analysis (Bradford, 1976) was
employed using the Bio-Rad reagent with human serum albumin
(KabiVitrum, Stockholm, Sweden) as a standard in order to
express antigen levels per mg of total protein. Triton X-100 up to a
concentration of 1% did not interfere with the protein determina-
tion in pellet extracts.
Statistical analysis
The strength of the associations of tPA and tPA:PAI-1 complex
levels determined in cytosols and pellet extracts with each other,
age and steroid hormone receptor levels was tested with Spearman
rank correlation (rs). The associations of tPA and tPA:PAI-1
complex with other clinical variables were tested with thetPA and tPA:PAI-1 complexes in breast cancer 289
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non-parametric Wilcoxon rank-sum test or the Kruskal–Wallis
test, including a Wilcoxon-type test for trends across ordered
groups where appropriate. RFS and OS probabilities were calcu-
lated by the actuarial method of Kaplan and Meier (Kaplan and
Meier, 1958). The log-rank test for trend was used to test ordered
variables. Both uni- and multivariate analyses were performed
using the Cox proportional hazard model, and the associated like-
lihood ratio test was used to test for differences. All computations
were done with the STATA statistical package, release 5.0 (STATA
Corp., College Station, TX, USA). Two-sided P-values below 0.05
were considered to be statistically significant.
RESULTS
tPA and tPA:PAI-1 complex in cytosols and pellet
extracts
The antigen levels of tPA determined in the cytosols varied from
0.02 to 216.75 ng mg–1 protein (mean 6.38; median 2.40) and those
in the pellet extracts varied from 0.06 to 2263.00 ng mg–1 protein
(mean 38.19; median 13.01). The cytosolic levels of tPA:PAI-1
complex ranged from 0.18 to 30.04 ng mg–1 protein (mean 2.34;
median 1.75) and in the pellet extracts from 0.20 to 374.00 (mean
9.91; median 6.57). As compared to the cytosolic levels of the
respective antigens, the levels determined in the pellet extracts
were approximately sixfold (tPA) and fourfold (tPA:PAI-1
complex) higher. However, the correlations between the levels in
cytosols and in the corresponding pellet extracts were statistically
significant (rs = 0.75, P < 0.001 for tPA and rs = 0.50, P < 0.001
for tPA:PAI-1 complex). Significant correlations were also found
between the levels of tPA and tPA:PAI-1 complex in cytosols
(rs = 0.30, P < 0.001) and pellet extracts (rs = 0.25, P < 0.001).
Relation of tPA and tPA:PAI-1 complex to patient and
tumour characteristics
The levels of tPA and tPA:PAI-1 complex determined in cytosols
and pellet extracts were related to patient and tumour characteris-
tics (Table 1). The levels of tPA and tPA:PAI-1 complex measured
in cytosols or pellet extracts were positively related with patient’s
age. The cytosolic level of tPA, as well as its level in pellet
extracts, was not related with menopausal status, while those of
tPA:PAI-1 complex were significantly higher in tumours from
post-menopausal patients. In general, tPA or tPA:PAI-1 complex
levels were negatively related with the size of the primary tumour.
In contrast, the levels of tPA and tPA:PAI-1 complex, measured
Table 2 Cox univariate and multivariate analyses of relapse-free and overall survival in 865 breast cancer patients
Factor Univariate analyses RFS Multivariate analyses RFS Univariate analyses OS  Multivariate analyses OS
P-value RHR (95% CI)a P-value RHR (95% CI)b P-value RHR (95% CI)a P-value RHR (95% CI)b
Age and menopausal status < 0.001c < 0.001c < 0.001c < 0.001c
Age/pre-menopausald 0.59 (0.46–0.77) 0.63 (0.49–0.81) 0.74 (0.53–1.05) 0.81 (0.57–1.14)
Age/post-menopausald 1.08 (0.92–1.26) 1.00 (0.85–1.17) 1.49 (1.27–1.76) 1.36 (1.15–1.61)
Post- vs pre-menopausale 1.68 (1.09–2.59) 1.38 (0.88–2.16) 1.51 (0.87–2.61) 1.19 (0.67–2.10)
Tumour size < 0.001 0.08 < 0.001 < 0.001
2–5 cm vs ≤ 2 cm 1.56 (1.24–1.95) 1.22 (0.96–1.56) 1.75 (1.34–2.29) 1.18 (0.88–1.58)
> 5 cm vs ≤ 2 cm 2.43 (1.72–3.42) 1.54 (1.04–2.28) 3.82 (2.69–5.40) 2.16 (1.46–3.21)
Nodal status < 0.001 < 0.001 < 0.001 0.004
N1–3 vs N0 1.22 (0.93–1.61) 1.51 (1.09–2.09) 1.83 (1.34–2.51) 2.34 (1.64–3.34)
N>3 vs N0 2.68 (2.11–3.41) 2.88 (2.12–3.91) 3.78 (2.86–5.00) 3.80 (2.71–5.35)
ERf < 0.001 0.64 (0.51–0.81) 0.05 0.75 (0.56–1.00) < 0.001 0.57 (0.45–0.74) 0.007 0.65 (0.48–0.88)
PgRf 0.02 0.76 (0.61–0.95) 0.83 0.97 (0.74–1.28) < 0.001 0.59 (0.46–0.75) 0.03 0.72 (0.53–0.96)
Adjuvant therapyg 0.05 0.76 (0.58–1.00) 0.007 0.65 (0.48–0.89) < 0.001 0.53 (0.40–0.72) 0.008 0.63 (0.44–0.89)
tPA cytosol 0.06 0.90h 0.07 0.94h
Q2 vs Q1 0.81 (0.61–1.07) 0.99 (0.73–1.34) 0.81 (0.58–1.11) 1.11 (0.79–1.57)
Q3 vs Q1 0.71 (0.53–0.96) 0.89 (0.64–1.24) 0.78 (0.56–1.08) 1.04 (0.72–1.50)
Q4 vs Q1 0.78 (0.58–1.04) 0.98 (0.71–1.37) 0.73 (0.52–1.02) 1.04 (0.71–1.53)
tPA pellet < 0.001 0.06 < 0.001 0.03
Q2 vs Q1 0.76 (0.57–1.00) 0.86 (0.65–1.15) 0.76 (0.56–1.02) 0.95 (0.69–1.30)
Q3 vs Q1 0.60 (0.45–0.81) 0.75 (0.55–1.04) 0.55 (0.39–0.76) 0.73 (0.51–1.05)
Q4 vs Q1 0.55 (0.41–0.73) 0.64 (0.46–0.89) 0.48 (0.34–0.67) 0.60 (0.41–0.88)
tPA:PAI-1 complex cytosol 0.01 0.03 < 0.001 < 0.001
Q2 vs Q1 1.27 (0.92–1.75) 1.26 (0.91–1.74) 1.81 (1.22–2.67) 1.91 (1.28–2.86)
Q3 vs Q1 1.42 (1.03–1.95) 1.51 (1.09–2.09) 1.67 (1.12–2.47) 1.92 (1.28–2.88)
Q4 vs Q1 1.47 (1.07–2.00) 1.59 (1.15–2.18) 2.25 (1.54–3.27) 2.62 (1.77–3.87)
tPA:PAI-1 complex pellet 0.81 0.35 0.10 0.03
Q2 vs Q1 1.11 (0.82–1.50) 1.09 (0.80–1.48) 1.10 (0.78–1.56) 1.14 (0.80–1.64)
Q3 vs Q1 1.09 (0.80–1.47) 1.15 (0.85–1.58) 1.20 (0.85–1.69) 1.35 (0.95–1.93)
Q4 vs Q1 1.05 (0.77–1.42) 1.33 (0.97–1.83) 1.24 (0.89–1.75) 1.71 (1.19–2.45)
aRelative hazard rate (RHR) with 95% confidence interval (CI) of univariate analyses. bRelative hazard rate (RHR) with 95% confidence interval (CI) of
multivariate analyses (final model, 841 patients; patients with missing values for ER and PgR (n = 15), and missing information on nodal status (n = 9) not
included) corrected for the basic model, including age/menopausal status, tumour size, nodal status, ER/PgR status, and adjuvant therapy; factors were added
separately to the basic model. cAge and menopausal status combined. dAge in decades tested separately for pre- and post-menopausal patients. ePost-
menopausal as compared with pre-menopausal. fCut-off points used for ER and PgR, 10 fmol mg–1 protein. gAdjuvant therapy (yes vs no) only for node-positive
patients. hP-values for the associated likelihood ratio test for the quarters (Q1–Q4) indicated: Q1, first quarter; Q2, second quarter; Q3, third quarter; Q4, fourth
quarter. The quartiles of the tPA antigen levels were successively 1.21, 2.40, 4.72 ng mg–1 (for cytosols) and 5.48, 13.01, 33.18 ng mg–1 (for pellet extracts); the
quartiles of the tPA:PAI-1 complex levels were successively 0.97, 1.75, 3.08 ng mg–1 (for cytosols) and 3.69, 6.57, 10.16 ng mg–1 (for pellet extracts).290 JH de Witte et al
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Table 3 Cox univariate and multivariate analyses of relapse-free and overall survival in 865 breast cancer patients
Factor Univariate analyses RFS Multivariate analyses RFS Univariate analyses OS  Multivariate analyses OS
P-value RHR (95% CI)a P-valuec RHR (95% CI)b P-value RHR (95% CIa P-valuec RHR (95% CI)b
PAI-1 cytosol < 0.001 < 0.001 < 0.001 < 0.001
Q2 vs Q1 1.15 (0.84–1.59) 1.31 (0.94–1.81) 1.23 (0.83–1.81) 1.42 (0.95–2.13)
Q3 vs Q1 1.50 (1.10–2.04) 1.55 (1.13–2.13) 1.73 (1.20–2.49) 1.80 (1.23–2.63)
Q4 vs Q1 2.05 (1.53–2.76) 2.12 (1.55–2.88) 2.61 (1.85–3.69) 2.69 (1.87–3.88)
PAI-1 pellet < 0.001 0.001 < 0.001 < 0.001
Q2 vs Q1 1.02 (0.75–1.39) 1.08 (0.78–1.49) 0.95 (0.66–1.38) 1.10 (0.75–1.62)
Q3 vs Q1 1.35 (1.00–1.83) 1.43 (1.05–1.95) 1.45 (1.03–2.05) 1.60 (1.12–2.29)
Q4 vs Q1 1.57 (1.17–2.12) 1.75 (1.28–2.38) 1.91 (1.36–2.67) 2.19 (1.53–3.12)
PAI-1/tPA cytosol < 0.001 0.06 < 0.001 < 0.004
Q2 vs Q1 0.90 (0.66–1.23) 1.04 (0.75–1.43) 0.77 (0.52–1.13) 0.84 (0.57–1.25)
Q3 vs Q1 1.15 (0.85–1.56) 1.07 (0.78–1.47) 1.45 (1.03–2.03) 1.27 (0.88–1.81)
Q4 vs Q1 1.63 (1.22–2.18) 1.47 (1.07–2.02) 1.85 (1.33–2.57) 1.64 (1.13–2.36)
PAI-1/tPA pellet < 0.001 0.004 < 0.001 < 0.001
Q2 vs Q1 1.04 (0.75–1.43) 1.22 (0.88–1.69) 0.98 (0.66–1.44) 1.21 (0.81–1.81)
Q3 vs Q1 1.45 (1.06–1.97) 1.33 (0.97–1.83) 1.89 (1.33–2.67) 1.68 (1.17–2.43)
Q4 vs Q1 1.87 (1.40–2.52) 1.82 (1.32–2.53) 2.15 (1.52–3.03) 2.05 (1.40–3.02)
aRelative hazard rate (RHR) with 95% confidence interval (CI) of univariate analyses. bRelative hazard rate (RHR) with 95% confidence interval (CI) of
multivariate analyses corrected for the basic model, including age/menopausal status, tumour size, nodal status, ER/PgR status, and adjuvant therapy; factors
were added separately to the basic model. cP-values for the associated likelihood ratio test for the quarters (Q1–Q4) indicated; Q1, first quarter; Q2, second
quarter; Q3, third quarter; Q4, fourth quarter. The quartiles of the PAI-1 antigen levels were successively 1.06, 1.62, 2.63 ngmg–1 (for cytosols) and 3.30, 5.28,
8.61 ng mg–1 (for pellet extracts); the quartiles of the PAI-1/tPA ratios were successively 0.27, 0.66, 1.65 ng mg–1 (for cytosols) and 0.15, 0.41, 1.32 ng mg –1 (for
pellet extracts).
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Figure 1 Actuarial relapse-free and overall survival curves for breast cancer patients stratified by the levels of tPA in pellet extracts (A and C) and of
tPA:PAI-1 complex in cytosols (B and D). Patients were divided into groups according to the quartiles (Q1– Q4) of the respective levels as indicated in the
legend to Table 2tPA and tPA:PAI-1 complexes in breast cancer 291
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either in cytosols or pellet extracts, were not related with nodal
status, except for tPA in pellet extracts, its levels decreasing with
advanced lymph node involvement. The levels of tPA determined
in cytosols and pellet extracts were significantly lower in poorly
differentiated tumours, whereas no relations were found between
the levels of tPA:PAI-1 complex and tumour grade. Overall,
higher levels of tPA and tPA:PAI-1 complex were measured in
steroid hormone-positive tumours, the correlation coefficients (rs)
observed ranging between 0.10 and 0.42.
Relation of tPA and tPA:PAI-1 complex to survival
In Cox univariate regression analysis, young pre-menopausal age,
post-menopausal status, the size of the primary tumour, the
number of positive lymph nodes, steroid hormone receptor-
negativity and adjuvant therapy in node-positive patients were
significantly associated with reduced RFS and OS (Table 2). When
divided into four groups (Q1 to Q4) by their respective quartiles,
decreasing levels of tPA in pellet extracts and increasing levels of
Table 4 Cox univariate and multivariate analyses of relapse-free and overall survival in 865 breast cancer patients
Factor Univariate analyses RFS Multivariate analyses RFS Univariate analyses OS Multivariate analyses OS
P-value RHR (95% CI)a P-valuec RHR (95% CI)b P-value  RHR (95% CI)a P-valuec RHR (95% CI)b
tPAfreecytosol 0.02 0.78 (0.64–0.97) 0.33 0.89 (0.71–1.12) 0.003 0.70 (0.55–0.88) 0.08 0.79 (0.61–1.03)
tPAfreepellet < 0.001 0.66 (0.54–0.82) 0.02 0.76 (0.60–0.96) < 0.001 0.58 (0.46–0.74) 0.002  0.66 (0.51–0.87)
PAI-1freecytosol < 0.001 1.52 (1.22–1.89) 0.002 1.43 (1.13–1.79) < 0.001 2.17 (1.68–2.81) < 0.001 2.01 (1.53–2.63)
PAI-1freepellet < 0.001 1.45 (1.18–1.80) < 0.001 1.45 (1.16–1.82) < 0.001 1.78 (1.40–2.28) < 0.001 1.70 (1.32–2.20)
aRelative hazard rate (RHR) with 95% confidence interval (CI) of univariate analyses. bRelative hazard rate (RHR) with 95% confidence interval (CI) of
multivariate analyses corrected for the basic model, including age/menopausal status, tumour size, nodal status, ER/PgR status, and adjuvant therapy; factors
were added separately to the basic model. cP-values for the associated likelihood ratio test for the median values of the levels of the free, uncomplexed forms
of tPA (tPAfree) and PAI-1 (PAI-1free). The median values in ng mg–1 protein were: 1.74 for tPAfree cytosol, 11.11 for tPAfree pellet, 1.26 for PAI-1free cytosol, 3.68
for PAI-1free pellet.
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Figure 2 Actuarial relapse-free and overall survival curves for breast cancer patients stratified by the combined levels of tPA and PAI-1 determined in cytosols
(A and C) and in pellet extracts (B and D). Patients were divided into groups with levels below (‘low’) and above (‘high’) the median value of the respective tPA
and PAI-1 levels as indicated in the legend to Table 1 and Table 3292 JH de Witte et al
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tPA:PAI-1 complex in cytosols showed a clear trend towards a
worse RFS and OS (Table 2, Figure 1). The levels of tPA in
cytosols and those of tPA:PAI-1 complex in the pellet extracts
were not significantly related with RFS and OS.
Cox multivariate regression analysis was performed to compare
the prognostic significance of tPA and tPA:PAI-1 complex with
that of the classical prognostic parameters (Table 2), these latter
variables comprising a basic multivariate model. In the basic
multivariate model, age, menopausal status, nodal status, ER status
and adjuvant therapy were all significantly associated with both
RFS and OS, nodal status being the strongest of the classical prog-
nostic factors. Tumour size and PgR status were only statistically
significant in predicting OS, not RFS (Table 2). Corrected for the
basic multivariate model, the levels of tPA:PAI-1 complex in
cytosols and pellet extracts were related with a poor RFS and OS,
although this relationship for the pellet extracts with RFS was
statistically not significant. The prognostic information provided
by the tPA:PAI-1 complex appeared to be stronger in cytosols as
compared to the pellet extracts. The levels of tPA did not signifi-
cantly add to the basic multivariate model with respect to both
RFS and OS, although, in the analysis for OS, the contribution of
tPA in pellet extracts reached statistical significance (P = 0.03)
(Table 2).
Recently, the antigen levels of PAI-1 were determined in the
same cytosols and pellet extracts, applying the same ELISA
framework (De Witte et al, 1998). The (total) levels of PAI-1
and tPA in both types of extracts were very weakly negatively
correlated with each other (rs = –0.073, P = 0.033, for cytosols;
rs = –0.12, P = 0.001, for pellet extracts). Since both factors have
opposite effects on patient prognosis, the ratio of PAI-1 to tPA
(PAI-1/tPA) was calculated as an alternative variable to be related
with survival. Both the antigen levels of PAI-1 and of the PAI-1:
tPA ratio, either in cytosols or in pellet extracts, were associated
with the rates of relapse and death, also when corrected for
the basic multivariate model (Table 3). After including PAI-1 in
the basic multivariate model, tPA did not further contribute to the
prognostic information already provided by PAI-1. Figure 2 shows
the actuarial RFS and OS curves of patients as a function of the
combined effect of (total) tPA and (total) PAI-1 in cytosols and
pellet extracts, both factors divided by their median value. Clearly,
patients with low levels of tPA in their tumours, which, in addition,
contain high levels of PAI-1 experienced a very poor prognosis. In
turn, patients with both high tPA and low PAI-1 tumour levels
encountered a favourable prognosis.
Finally, the levels of the free, uncomplexed forms of tPA and
PAI-1 in cytosols and pellet extracts were estimated by subtraction
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Figure 3 Actuarial overall survival curves for breast cancer patients stratified by the estimated levels of free, uncomplexed tPA (A and C) and of free,
uncomplexed PAI-1 (B and D) in cytosols and in pellet extracts. Patients were divided into groups according to the median values indicated in the legend to
Table 4of the (molar) concentrations of the tPA:PAI-1 complexes from the
(total) concentrations of tPA and PAI-1, respectively. In univariate
analyses with the corresponding median values chosen to discrim-
inate between low-risk and high-risk patients, high levels of
uncomplexed tPA in cytosols and pellet extracts were significantly
associated with prolonged RFS and OS (Table 4, Figure 3A, C). In
contrast, high levels of uncomplexed PAI-1 in cytosols and pellet
extracts appeared to be related with a significantly reduced RFS
and OS (Table 4; Figure 3B, D). Moreover, in multivariate
analyses corrected for the classical prognostic factors, uncom-
plexed PAI-1 in cytosols and in pellet extracts was found to be
related with both poor RFS and OS, comparably strong as total
PAI-1. The uncomplexed form of tPA measured in pellet extracts,
but not in cytosolic extracts, added significantly to the basic multi-
variate model with respect to both RFS and OS (Table 4).
DISCUSSION
In the present study, the prognostic impact of tPA antigen levels in
a relatively large series of 865 breast cancer patients was evaluated
employing a newly developed ELISA. The antigen levels were
determined in cytosols routinely used for steroid hormone receptor
analyses, as well as in extracts of 100 000 g pellets, which may
be considered as incidental products of ultracentrifugation when
preparing the cytosolic fractions. Its appearance in the pellet
extracts may suggest the presence of a membrane-associated form
of tPA. Indeed, receptors for tPA have been identified on the
surfaces of vascular endothelial cells (Dudani and Ganz, 1996),
which, in turn, are regarded as the primary source of tPA (Levin
et al, 1997). In univariate analyses, high levels of tPA in pellet
extracts were significantly associated with a lower probability of
developing recurrences and of experiencing an early death.
However, in multivariate analyses, after correction for the classical
prognostic factors, elevated levels of tPA in pellet extracts
appeared only as a weak predictor of improved OS (P = 0.03), but
not RFS (P = 0.06). These findings resemble those obtained by
Jänicke et al (1991) who determined tPA in detergent extracts of
breast cancer tissue by ELISA, and showed that patients with a
high tPA content tended to have a better prognosis than those with
low, or no, detectable tPA content. However, the difference was
not statistically significant. Furthermore, Duggan et al (1997),
applying an ELISA to breast tumour extracts prepared with deter-
gent-containing buffer, determined tPA to be an independent prog-
nostic factor in breast cancer, with a calculated relative risk of
relapse and of death corresponding to 0.56 and 0.47, respectively.
Regarding the cytosolic extracts of breast tumour tissue, their tPA
antigen levels did not have any prognostic impact on the rates of
relapse or death. These findings are in apparent contrast to a
previous report by Duffy et al (1988) who showed that patients
with high cytosolic levels of tPA had a significantly longer
disease-free interval and survival compared to patients with low
tPA levels. The median follow-up period, however, was consider-
ably shorter (26 months). In agreement with other investigations,
the cytosolic levels of tPA were positively related to steroid
hormone receptor (ER and/or PgR) status (Duffy et al, 1986;
Needham et al, 1988; Schmitt et al, 1990; Jänicke et al, 1991; Rella
et al, 1993). In this respect, the observed correlation of high tPA
antigen levels with good prognosis may be related to the fact that
tPA is an oestrogen-inducible enzyme (Butler et al, 1983; Mira-Y-
Lopez and Ossowski, 1987), the presence of ER itself generally
being associated with good prognosis in breast carcinomas (Table
2). Therefore, the presence of tPA may be directly representative
of a functional, biologically active ER system, important for plan-
ning endocrine therapy, as has been suggested by Rella et al
(1993). The positive clinical impact of tPA on survival is also
expressed by the combined prognostic value of tPA and PAI-1
measured in cytosols but mainly in pellet extracts (Figure 2),
exemplifying that tPA abolishes the unfavourable effect of PAI-1
on prognosis. An interesting finding of the present study concerns
the prognostic impact of tPA:PAI-1 complex measured in the
breast tumour cytosols on survival. In multivariate analyses,
cytosolic tPA:PAI-1 complex provided prognostic information,
which appeared to be almost as strong as cytosolic PAI-1 with
respect to RFS and, especially, OS. This latter observation is in
line with the supposition that the levels of tPA:PAI-1 complex in
tumour tissue extracts may indirectly reflect the level of PAI-1
which has been originally active, since only the active form of
PAI-1 is able to form complexes with tPA (Hekman and Loskutoff,
1985). Although PAI-1 was shown to be a strong independent
prognostic parameter also in pellet extracts, tPA:PAI-1 complex
did not have prognostic impact on RFS and was only a weak
predictor of OS when measured in this type of extracts.
Consequently, this latter finding may suggest that the prognostic
relevance exerted by PAI-1 in the pellet extracts does not originate
from its complex with tPA, but may be provided by the free,
uncomplexed form of PAI-1. Presumably, this also accounts for the
prognostic significance of (free, uncomplexed) tPA in the pellet
extracts (see below). From an analytical–chemical point of view,
the ELISA for tPA:PAI-1 complex can be considered as being
highly specific for the component to be assessed. While the tPA
ELISA detects both the free and complexed forms of tPA, the
tPA:PAI-1 complex ELISA selectively quantifies only one molec-
ular variant of tPA, i.e. its complex with PAI-1, without being
sensitive towards the separate components, tPA and PAI-1
(Grebenschikov et al, 1997). Moreover, the results obtained with
the tPA:PAI-1 complex ELISA may be regarded as being highly
reliable, since the tPA:PAI-1 complex standard used for quantita-
tion of the assay results is directly comparable to the analyte to be
assessed. In contrast, the single-chain recombinant tPA standard
employed in the tPA ELISA, clearly is not fully representative of
the different molecular forms of tPA present in the clinical samples
(see below), a complication inherently linked to assays attempting
to quantify a heterogenous component (Benraad et al, 1996).
The PAI-1/tPA ratio, introduced as an alternative parameter, also
provided strong prognostic information, high levels in cytosols as
well as in pellet extracts predicting both reduced RFS and OS.
Most likely, a high PAI-1:tPA ratio is representative of a large
excess of (free, uncomplexed) PAI-1 predictive of poor prognosis,
while a low PAI-1/tPA ratio reflects a relative excess of (free,
uncomplexed) tPA with a favourable effect on prognosis. This
consideration may underlie the observed associations of high
levels of the free, uncomplexed forms of both PAI-1 and tPA in
cytosols and pellet extracts with successively a poor and good
prognosis. However, one has to realize that the levels of the free,
uncomplexed forms are just estimations based on subtraction of
tPA:PAI-1 complex levels from the total antigen levels of tPA and
PAI-1, the more so as other complexed forms such as tPA:PAI-2
and uPA:PAI-1 might also be detected in the ELISA for (total) tPA
and (total) PAI-1, respectively. Moreover, as compared to the free,
uncomplexed forms, each of the various complexes will be
detected with different efficiencies in the standard ELISAs, which,
in addition, make use of standards or calibrators (recombinant
tPA and tPA:PAI-1 complexes in breast cancer 293
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single-chain tPA and latent human PAI-1) which may not be
completely representative of the clinical samples to be analysed.
Notwithstanding these limitations, the observed impact of the free,
uncomplexed forms on survival are in accordance with our expec-
tations of a favourable (tPA) and an unfavourable (PAI-1) prog-
nostic marker. Accordingly, the development of immunoassays for
the selective detection of specific forms of the various components
of the plasminogen activation system, i.e. tPA:PAI-1 complex, free
uncomplexed tPA and/or free, uncomplexed PAI-1, may be a
useful adjunct to the analyses of the separate components (tPA
and/or PAI-1) by ELISA, the latter assay results representing at
best the total antigen content of the clinical sample.
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